Trialfacts

FEBRUARY 1, 2023

lbs Must not be diagnosed with cow’s milk protein allergy by a healthcare professional Must be able to participate in this study for 28 days Parent or legal guardian must be fluent in English This research study is taking place in several locations. To see if there is a research site near you, please see below.

Research 52

Research Clinical Research Allergies Protein 52

Trialfacts

JANUARY 11, 2023

Researchers are exploring a potential new treatment for CIPN and are looking for volunteers to participate in a multi-site research study in Australia. This study is exploring a medication that is nearly identical to a natural protein already produced by the body when we exercise in order to help reduce inflammation.

Research 52

Research Clinical Research Allergies Protein 52

Trialfacts

FEBRUARY 14, 2023

lbs Must not be diagnosed with cow’s milk protein allergy by a healthcare professional Must be able to participate in this study for 28 days Parent or legal guardian must be fluent in English This research study is taking place in several locations. To see if there is a research site near you, please see below.

Research 52

Research Allergies Protein Clinical Research 52

XTalks

SEPTEMBER 21, 2023

This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). The initiation of our first clinical trial evaluating VIR-1388 is an important clinical milestone in our pursuit of developing an HIV vaccine and we are grateful to all our partners for their support of this Phase I trial.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. Researchers at the Sanford Burnham Prebys Medical Discovery Institute and the University of Glasgow have early proof a combination strategy may work in AML.

Research 52

Research Protein Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. About mRNA-1273.

Vaccination 52

Vaccination Vaccine Medicine Clinical Trials 52